Impact of non-high-density lipoprotein cholesterol in mortality and cardiovascular events among middle-aged Russian men: 40 years ago and now
Aim . To evaluate the non-high density lipoprotein cholesterol (non-HDL-C) predictive ability in relation to cardiovascular events, all-cause and cause-specific mortality and among middle-aged Russian men now and 40- years ago. Material and methods . For analysis data from 9507 men aged 35-64 without cardiovascular disease (CVD) who did not receive lipid-lowering therapy, participants of two independent population prospective cohort studies — 40-year retrospective (Russian LRC) and conducted at the present time (ESSE-RF) — were used. In the analysis, all-cause mortality, cancer and CVD mortality, and non-fatal CVD (myocardial infarction and STEMI stroke) were assessed. The follow-up period for the LRС study was 10 years, and for the ESSE-RF study, it was 7.8 years. Results . The mean value of non-HDL-C was 0.3 mmol/L higher among participants from the Russian LRC cohort than among men from the ESSE-RF cohort. Low non-HDL-C levels were associated with an increased risk of all-cause mortality. A strong link between high levels of non-HDL-C and the development of fatal and nonfatal CVD events was also found in both cohorts. Men with non-HDL-C levels ≥4.5 mmol/L in the LRC study and ≥4.2 mmol/L in the ESSE-RF study had a significantly increased risk of fatal and non-fatal CVDs (63% and 27%, respectively) and decreased risk of cancer mortality (28% and 50%, respectively). Conclusion . Downwards trends in non-HDL-C levels over the past 40 years were indicated. The study identified a decline of non-HDL-C in the general population level since the 1970s of the 20th century. Up to the present time, there is still a non-linear relationship between the level of non-HDL-C and total mortality, that could be explained by the presence of differently directed associations between this parameter, cancer mortality and the development of fatal and non-fatal CVDs.
Authors
- Б. М. Назаров (ORCID: https://orcid.org/0000-0003-2145-1284)
- Oleg Ivlev (ORCID: https://orcid.org/0000-0002-3663-6305)
- V. A. Metelskaya (ORCID: https://orcid.org/0000-0001-8665-9129)
- Yu. А. Balanova (ORCID: https://orcid.org/0000-0001-8011-2798)
- N. A. Imaeva (ORCID: https://orcid.org/0000-0002-8058-1081)
- А. Э. Имаева (ORCID: https://orcid.org/0000-0002-9332-0622)
- Vladimir Aleksandrovich Kutsenko (ORCID: https://orcid.org/0000-0001-9844-3122)
- Svetlana Anatolievna Shalnova (ORCID: https://orcid.org/0000-0003-2087-6483)
- Е. B. Yarovaya (ORCID: https://orcid.org/0000-0002-6615-4315)
- Капустина Анна Владимировна (ORCID: https://orcid.org/0000-0002-9624-9374)
- Oksana M. Drapkina (ORCID: https://orcid.org/0000-0002-4453-8430)
Institutions
- National Research Center for Preventive Medicine (RU)
- Ministry of Health of the Russian Federation (RU)
- Family Healthcare (US)
Publication Details
- Journal
- Rational Pharmacotherapy in Cardiology
- Published
- 2024-11-03
- DOI
- https://doi.org/10.20996/1819-6446-2024-3101
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00